JOA - 2026-10-07 - Journal Article
Systemic Exposure and Renal Safety After Intrawound Vancomycin Powder in Primary Total Knee Arthroplasty: A Prospective Comparative Cohort Study.
Bingol O, Karlidag T, Ozsoy HE, Aydin T, Keskin OH, Ozkurt B
Topics
Key Takeaway
Intrawound 1g vancomycin powder in primary TKA produced detectable serum levels in only 20% of patients (median 0.28 mg/L, far below therapeutic range) and caused no increase in AKI (6.9% vs 6.2%), but also failed to reduce PJI or wound complications.
Summary Depth
Choose how much analysis to show on this article page.
Summary
This prospective comparative cohort study evaluated systemic vancomycin absorption and renal safety after 1g intrawound vancomycin powder in primary TKA versus no local antibiotic. Serum vancomycin was undetectable (<1.00 mg/L) in 80% of the vancomycin group, and among those with measurable levels the median was 0.28 mg/L; AKI rates were equivalent between groups (6.9% vs 6.2%, OR 1.13, 95% CI 0.42–3.04). No statistically significant difference in PJI, superficial infection, or wound dehiscence was observed.
Key Limitation
The study is critically underpowered to detect a statistically significant reduction in PJI, as a sample of 260 patients provides insufficient event rate to draw conclusions about infection efficacy.
Original Abstract
BACKGROUND
Periprosthetic joint infection (PJI) is a devastating complication after total knee arthroplasty (TKA). Intrawound vancomycin powder has been proposed as a local prophylactic measure, but concerns remain regarding systemic absorption and nephrotoxicity. This study evaluated systemic absorption, renal safety, and postoperative infection outcomes after intrawound vancomycin use in primary TKA.
METHODS
This prospective comparative cohort study included 260 patients who underwent primary TKA at a single tertiary care center: 130 in the vancomycin cohort and 130 in the control cohort. The vancomycin cohort received one gram of intrawound vancomycin powder before closure. Serum vancomycin levels were measured 12 hours postoperatively. Serial renal function and kidney disease: Improving Global Outcomes (KDIGO)-defined acute kidney injury (AKI) was analyzed in all patients. Infection and wound-complication outcomes were assessed in patients who completed at least six months of follow-up.
RESULTS
The 12-hour serum vancomycin levels were below the laboratory reporting threshold (less than 1.00 mg/L) in 104 of 130 patients (80.0%). Among the remaining 26 patients who had numerical values, the median concentration was 0.28 mg/L (interquartile range [IQR], 0.21 to 1.26; range, 0.01 to 2.76 mg/L), which was well below systemic therapeutic levels. Serum vancomycin concentration was not correlated with early changes in serum creatinine or estimated glomerular filtration rate (Spearman ρ range, -0.08 to -0.03; all P ≥ 0.720). AKI occurred in nine patients (6.9%) in the vancomycin group and eight patients (6.2%) in the control group (odds ratio, 1.13; 95% confidence interval [CI], 0.42 to 3.04; P = 1.000). All AKI events in the vancomycin group were stage 1. Surgery-related complication rates were similar between groups, with no statistically significant differences in PJI, superficial infection, or wound dehiscence.
CONCLUSION
Intrawound administration of one gram of vancomycin powder in primary TKA resulted in minimal systemic exposure and showed no clinically meaningful nephrotoxicity signal. However, it was not associated with a statistically significant reduction in infection or wound-complication outcomes; therefore, these data do not support its routine prophylactic use in primary TKA.